Compare Stocks → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNASDAQ:DMACNASDAQ:GANXNASDAQ:GRTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsDMACDiaMedica Therapeutics$2.39-4.0%$2.85$1.50▼$4.75$90.72M1.6942,525 shs21,009 shsGANXGain Therapeutics$3.18+1.0%$4.16$2.00▼$6.19$51.58M0.43156,778 shs71,353 shsGRTXGalera Therapeutics$0.18$0.20$0.09▼$3.59$10.01M2.172.44 million shs801,588 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-88.34%DMACDiaMedica Therapeutics-4.23%-1.97%-11.70%-11.70%+44.77%GANXGain Therapeutics-0.94%-6.25%-25.88%-5.41%-36.62%GRTXGalera Therapeutics-6.25%+16.18%-22.98%+6.29%-93.21%Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ADMACDiaMedica Therapeutics0.8106 of 5 stars3.53.00.00.00.60.00.0GANXGain Therapeutics3.3122 of 5 stars3.55.00.00.03.02.50.6GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/ADMACDiaMedica Therapeutics3.00Buy$7.00192.89% UpsideGANXGain Therapeutics3.00Buy$8.33162.05% UpsideGRTXGalera Therapeutics1.75ReduceN/AN/ACurrent Analyst RatingsLatest DMAC, GANX, ADMP, and GRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/27/2024GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AGANXGain Therapeutics$50K1,031.59N/AN/A$0.97 per share3.28GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/ADMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/20/2024 (Estimated)GANXGain Therapeutics-$22.27M-$1.71N/AN/AN/AN/A-193.03%-123.21%5/10/2024 (Estimated)GRTXGalera Therapeutics-$59.08M-$1.41N/A∞N/AN/AN/A-137.47%5/9/2024 (Estimated)Latest DMAC, GANX, ADMP, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023GANXGain Therapeutics-$0.32-$0.29+$0.03-$0.29N/AN/A3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19DMACDiaMedica TherapeuticsN/A19.2719.27GANXGain Therapeutics0.043.593.59GRTXGalera TherapeuticsN/A4.364.36OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%DMACDiaMedica Therapeutics10.12%GANXGain Therapeutics11.97%GRTXGalera Therapeutics50.77%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%DMACDiaMedica Therapeutics7.20%GANXGain Therapeutics11.00%GRTXGalera Therapeutics6.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableGANXGain Therapeutics2816.22 million14.44 millionOptionableGRTXGalera Therapeutics3154.39 million50.64 millionOptionableADMP, GANX, DMAC, and GRTX HeadlinesSourceHeadlineGalera Therapeutics (NASDAQ:GRTX) Trading Down 3.8%americanbankingnews.com - April 16 at 1:48 AMGalera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory Challengesmsn.com - April 1 at 5:26 AMGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updatesfinanznachrichten.de - March 28 at 2:09 PMGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updatesglobenewswire.com - March 28 at 7:00 AMGRTX Apr 2024 0.500 callfinance.yahoo.com - March 16 at 9:07 AMGalera Therapeutics, Inc. (GRTX)nz.finance.yahoo.com - March 12 at 5:23 PMGalera Therapeutics, Inc.edition.cnn.com - February 27 at 7:25 AMGalera Therapeutics Inc (GRTX)investing.com - February 4 at 12:37 AMGalera Therapeutics Stock (NASDAQ:GRTX) Dividends: History, Yield and Datesbenzinga.com - February 4 at 12:37 AMGalera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17finance.yahoo.com - January 21 at 2:16 PMLocal publicly traded stocks lag far behind national indices in 2023bizjournals.com - January 16 at 1:33 PMDow Tumbles Over 200 Points; US Trade Gap Narrows In Novembermsn.com - January 9 at 2:28 PMGalera Therapeutics (GRTX) Price Target Increased by 7.14% to 0.38msn.com - November 28 at 2:59 AMGalera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinanznachrichten.de - November 14 at 8:41 AMGalera Therapeutics: Q3 Earnings Insightsbenzinga.com - November 14 at 8:41 AMGalera Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinance.yahoo.com - November 14 at 8:41 AMGalera Therapeutics's Earnings Outlookbenzinga.com - November 13 at 2:56 PMUnderstanding the Risks of Investing in Galera Therapeutics Inc (GRTX)knoxdaily.com - November 8 at 7:21 AMUS Stocks Fall; Pfizer Swings To Q3 Lossbenzinga.com - November 1 at 5:19 PMGalera Therapeutics Inc (GRTX) rating downgrades by Piper Sandlerknoxdaily.com - November 1 at 5:19 PMDow Gains 50 Points; Global Payments Posts Upbeat Earningsbenzinga.com - October 31 at 3:16 PMGalera Therapeutics warns of potential shutdown as it halts clinical trials and stock tanksbizjournals.com - October 31 at 3:16 PMWhy Is Cancer Focused Galera Therapeutics Stock Sinking Today?msn.com - October 31 at 3:16 PMGalera plunges after citing risks to business continuitymsn.com - October 31 at 3:16 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Gain TherapeuticsNASDAQ:GANXGain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.